Exicure (XCUR) to Present 89.7% Success Rate Data at ASTCT Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: Newsfilter
- Research Presentation: Exicure will showcase data from its open-label, multicenter Phase 2 trial at the ASTCT meeting from February 4-7, 2026, highlighting the application of burixafor in autologous hematopoietic cell transplantation for multiple myeloma patients, achieving an impressive 89.7% success rate for the primary endpoint, demonstrating both efficacy and safety of the therapy.
- Therapeutic Innovation: The study indicates that the combination of burixafor with propranolol and G-CSF effectively mobilizes hematopoietic progenitor cells, addressing mobilization challenges faced by multiple myeloma patients, particularly in the context of lenalidomide and daratumumab treatment.
- Clinical Application Potential: By blocking CXCR4, burixafor is expected to enhance stem cell mobilization for conditions like multiple myeloma and sickle cell disease, providing a reliable collection strategy for patients who may encounter barriers to successful stem cell collection.
- Future Research Plans: Exicure is also planning a chemosensitization trial in acute myeloid leukemia, leveraging burixafor's ability to mobilize malignant cells from protective bone marrow niches to improve chemotherapy effectiveness, further expanding its therapeutic potential in hematologic diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XCUR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XCUR
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Exicure Faces Nasdaq Delisting Risk Due to Equity Shortfall
- Delisting Notification: Exicure received a notification from Nasdaq on June 5, 2026, indicating a violation of Listing Rule 5550(b)(1) due to failing to maintain a minimum stockholders' equity of $2.5 million, thus facing delisting risk.
- Financial Disclosure: In its recent Form 10-Q filing, Exicure reported only $2.1 million in stockholders' equity, failing to meet Nasdaq's alternative listing standards, highlighting inadequate market values of listed securities and minimal net income from continuing operations.
- Management Response: The management team has implemented cost-reduction and restructuring initiatives, terminating non-essential consulting arrangements to address financial difficulties caused by executive separation-related expenses and obligations, aiming to improve the financial position.
- Compliance Plan Timeline: Nasdaq has granted Exicure up to 45 calendar days until July 20, 2026, to submit a durable plan for regaining compliance, and if accepted, the company may receive a 180-day extension to restore compliance, although there is currently no immediate impact on its common stock.
See More
Exicure Receives Nasdaq Compliance Notification Due to Delayed 10-Q Filing
- Compliance Notification: Exicure received a notification from Nasdaq's Listing Qualifications Department on May 28, 2026, indicating non-compliance due to the delayed filing of its 10-Q report for the quarter ending March 31, 2026, primarily attributed to changes in financial reporting personnel and procedures.
- Expected Compliance Restoration: Following the notification, Exicure filed its 10-Q report with the SEC on May 29, 2026, and anticipates regaining compliance with Nasdaq rules, which could help restore investor confidence and stabilize its stock price.
- Stock Price Fluctuation: Over the past year, XCUR's stock has traded between $2.62 and $10.80, closing at $3.33, up 4.39% on the last trading day, indicating cautious optimism in the market regarding its future performance.
- Pre-Market Trading Performance: Despite the recent closing gain, XCUR is down 3.90% in pre-market trading at $3.20, suggesting that investor concerns over compliance issues may impact short-term stock performance.
See More
Exicure Receives Nasdaq Non-Compliance Notice
- Non-Compliance Notice: Exicure received a Nasdaq non-compliance notice on May 28, 2026, due to its failure to timely file its Q1 2026 report, which could impact the company's credibility in the capital markets and investor confidence.
- Reason for Delay: The filing delay was primarily caused by changes in financial reporting personnel and related filing procedures, indicating instability in the company's internal management and processes, which may lead to reduced financial transparency in the future.
- Historical Financial Data: Historical earnings data for Exicure shows fluctuations in past reports, and the failure to submit timely filings may raise investor concerns about its financial health, potentially affecting stock performance.
- Potential Consequences: If Exicure fails to resolve compliance issues within the stipulated time, it may face further regulatory actions, which could jeopardize its listing status on Nasdaq, posing challenges for future financing and operations.
See More
Exicure Partners with Adbiotech for Burixafor Development
- Co-Development Agreement: Exicure has signed a co-development agreement with Korean biotech firm Adbiotech to utilize Burixafor for combination therapies targeting hematological diseases, marking a strategic expansion in the biopharmaceutical sector.
- Drug Development Background: Burixafor (GPC-100) is an investigational drug that has successfully completed a Phase 2 clinical trial for multiple myeloma and is currently being explored for various hematological indications, indicating its broad clinical potential.
- Defined Research Focus: Under the agreement, Adbiotech will conduct in vitro studies for preclinical validation, while Exicure will lead the clinical and regulatory strategy, ensuring a smooth development process for the drug.
- IND Submission Goal: The two companies are collaborating to advance research on Burixafor with the aim of submitting an investigational new drug (IND) application, further propelling the drug's path to market.
See More
Exicure Partners with Adbiotech for Burixafor Development
- Co-Development Agreement: Exicure has entered into a co-development agreement with Korea's Adbiotech to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas, marking a strategic expansion in the biotechnology sector.
- Clinical Trial Foundation: Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, establishing a foundation for further evaluation in hematologic indications such as acute myeloid leukemia and sickle cell disease, indicating its potential applicability in treatment.
- Research and Development Support: Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and lead clinical and regulatory strategy, ensuring the smooth progression of the research.
- Future Development Plans: The parties intend to conduct in vivo validation studies and may advance selected programs into IND-enabling studies and clinical trials based on further agreements, demonstrating a strong commitment to future clinical development.
See More
Exicure Partners with Adbiotech for Combination Therapy Development
- Co-Development Agreement: Exicure has entered into a co-development agreement with Korea-based Adbiotech to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas, indicating a strategic expansion into various indications.
- Clinical Trial Foundation: Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, providing a solid foundation for further evaluation in hematologic indications such as acute myeloid leukemia and sickle cell disease, potentially supporting future clinical development.
- Research and Funding Support: Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and lead clinical and regulatory strategy, with plans to secure funding for future clinical development.
- Future Development Plans: The parties intend to conduct in vivo validation studies and may advance selected programs into IND-enabling studies and clinical trials, reflecting a strong commitment to exploring Burixafor's potential in combination therapies.
See More
Exicure Faces Nasdaq Delisting Risk Due to Equity Shortfall
- Delisting Notification: Exicure received a notification from Nasdaq on June 5, 2026, indicating a violation of Listing Rule 5550(b)(1) due to failing to maintain a minimum stockholders' equity of $2.5 million, thus facing delisting risk.
- Financial Disclosure: In its recent Form 10-Q filing, Exicure reported only $2.1 million in stockholders' equity, failing to meet Nasdaq's alternative listing standards, highlighting inadequate market values of listed securities and minimal net income from continuing operations.
- Management Response: The management team has implemented cost-reduction and restructuring initiatives, terminating non-essential consulting arrangements to address financial difficulties caused by executive separation-related expenses and obligations, aiming to improve the financial position.
- Compliance Plan Timeline: Nasdaq has granted Exicure up to 45 calendar days until July 20, 2026, to submit a durable plan for regaining compliance, and if accepted, the company may receive a 180-day extension to restore compliance, although there is currently no immediate impact on its common stock.
See More
Exicure Receives Nasdaq Compliance Notification Due to Delayed 10-Q Filing
- Compliance Notification: Exicure received a notification from Nasdaq's Listing Qualifications Department on May 28, 2026, indicating non-compliance due to the delayed filing of its 10-Q report for the quarter ending March 31, 2026, primarily attributed to changes in financial reporting personnel and procedures.
- Expected Compliance Restoration: Following the notification, Exicure filed its 10-Q report with the SEC on May 29, 2026, and anticipates regaining compliance with Nasdaq rules, which could help restore investor confidence and stabilize its stock price.
- Stock Price Fluctuation: Over the past year, XCUR's stock has traded between $2.62 and $10.80, closing at $3.33, up 4.39% on the last trading day, indicating cautious optimism in the market regarding its future performance.
- Pre-Market Trading Performance: Despite the recent closing gain, XCUR is down 3.90% in pre-market trading at $3.20, suggesting that investor concerns over compliance issues may impact short-term stock performance.
See More
Exicure Receives Nasdaq Non-Compliance Notice
- Non-Compliance Notice: Exicure received a Nasdaq non-compliance notice on May 28, 2026, due to its failure to timely file its Q1 2026 report, which could impact the company's credibility in the capital markets and investor confidence.
- Reason for Delay: The filing delay was primarily caused by changes in financial reporting personnel and related filing procedures, indicating instability in the company's internal management and processes, which may lead to reduced financial transparency in the future.
- Historical Financial Data: Historical earnings data for Exicure shows fluctuations in past reports, and the failure to submit timely filings may raise investor concerns about its financial health, potentially affecting stock performance.
- Potential Consequences: If Exicure fails to resolve compliance issues within the stipulated time, it may face further regulatory actions, which could jeopardize its listing status on Nasdaq, posing challenges for future financing and operations.
See More
Exicure Partners with Adbiotech for Burixafor Development
- Co-Development Agreement: Exicure has signed a co-development agreement with Korean biotech firm Adbiotech to utilize Burixafor for combination therapies targeting hematological diseases, marking a strategic expansion in the biopharmaceutical sector.
- Drug Development Background: Burixafor (GPC-100) is an investigational drug that has successfully completed a Phase 2 clinical trial for multiple myeloma and is currently being explored for various hematological indications, indicating its broad clinical potential.
- Defined Research Focus: Under the agreement, Adbiotech will conduct in vitro studies for preclinical validation, while Exicure will lead the clinical and regulatory strategy, ensuring a smooth development process for the drug.
- IND Submission Goal: The two companies are collaborating to advance research on Burixafor with the aim of submitting an investigational new drug (IND) application, further propelling the drug's path to market.
See More
Exicure Partners with Adbiotech for Burixafor Development
- Co-Development Agreement: Exicure has entered into a co-development agreement with Korea's Adbiotech to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas, marking a strategic expansion in the biotechnology sector.
- Clinical Trial Foundation: Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, establishing a foundation for further evaluation in hematologic indications such as acute myeloid leukemia and sickle cell disease, indicating its potential applicability in treatment.
- Research and Development Support: Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and lead clinical and regulatory strategy, ensuring the smooth progression of the research.
- Future Development Plans: The parties intend to conduct in vivo validation studies and may advance selected programs into IND-enabling studies and clinical trials based on further agreements, demonstrating a strong commitment to future clinical development.
See More
Exicure Partners with Adbiotech for Combination Therapy Development
- Co-Development Agreement: Exicure has entered into a co-development agreement with Korea-based Adbiotech to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas, indicating a strategic expansion into various indications.
- Clinical Trial Foundation: Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, providing a solid foundation for further evaluation in hematologic indications such as acute myeloid leukemia and sickle cell disease, potentially supporting future clinical development.
- Research and Funding Support: Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and lead clinical and regulatory strategy, with plans to secure funding for future clinical development.
- Future Development Plans: The parties intend to conduct in vivo validation studies and may advance selected programs into IND-enabling studies and clinical trials, reflecting a strong commitment to exploring Burixafor's potential in combination therapies.
See More
